2026-01-02 - Analysis Report
Okay, let's break down the analysis of Natera Inc. (NTRA) based on the provided data.

**0. Report Introduction**

This report provides an analysis of Natera Inc. (NTRA), a diagnostics company, focusing on its performance relative to the S&P 500 (VOO), recent stock fluctuations, market indicators, news events, analyst opinions, earnings, and financial information.

**1. Return Rate Comparison**

*   **Company Overview:** Natera Inc. is a diagnostics company focusing on cell-free DNA testing.
*   **NTRA Cumulative Return:** 127.57%
*   **VOO Cumulative Return:** 105.07%
*   **Divergence:**
    *   Current Divergence: 22.5
    *   Relative Divergence: 46.6 (This means the current divergence is near the middle of its historical range.)

*   **Analysis of Alpha, Beta, CAGR, MDD Table:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 63.0% | 80.2% | 34.0% | 1.5 | 1.9 |
| 2017-2019  | 276.0% | 80.2% | 234.0% | 1.7 | 4.7 |
| 2018-2020  | 856.0% | 80.5% | 823.0% | 1.3 | 13.9 |
| 2019-2021  | 587.0% | 80.5% | 511.0% | 1.4 | 13.0 |
| 2020-2022  | 15.0% | 90.4% | -4.0% | 1.4 | 5.6 |
| 2021-2023  | -41.0% | 92.2% | -70.0% | 1.6 | 8.7 |
| 2022-2024  | 124.0% | 87.1% | 94.0% | 1.5 | 22.1 |
| 2023-2025  | 434.0% | 77.9% | 366.0% | 1.3 | 31.9 |

    *   **CAGR (Compound Annual Growth Rate):** Shows substantial growth potential, though highly variable across different periods.  The CAGR has fluctuated wildly, indicating periods of rapid growth followed by periods of decline.
    *   **MDD (Maximum Drawdown):** High MDD values consistently across all periods indicate significant risk.
    *   **Alpha:** Indicates NTRA's performance relative to its benchmark.  High alpha values in some periods (e.g., 2018-2020) mean the stock significantly outperformed expectations, but negative alpha in other periods (e.g., 2021-2023) means it underperformed.
    *   **Beta:**  A Beta consistently above 1 suggests that NTRA is more volatile than the market (S&P 500).
    *   **Cap(B):** Market Cap in Billions, shows the company's market capitalization over the specified period.

**2. Recent Stock Price Fluctuations**

*   **Current Close Price:** 229.09
*   **Previous Close Price:** 229.98
*   **Change:** -0.39
*   **5-day SMA:** 231.93
*   **20-day SMA:** 233.21
*   **60-day SMA:** 211.50

*   **Analysis:** The current price is slightly below the 5-day and 20-day SMAs, but well above the 60-day SMA. This suggests a possible short-term downward trend after a recent upward movement, while the 60-day SMA suggests it is still in a medium term upward trend.

**3. Market Indicators**

*   **MRI (Market Risk Indicator):** 0.9 (Medium Investment Recommended)
*   **RSI (Relative Strength Index):** 42.73 (Neutral - not overbought or oversold)
*   **PPO (Percentage Price Oscillator):** -0.72 (Slightly bearish)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** -1.8 (Short-term decline)
*   **Expected Return (%):** -65.2% (Negative expected return relative to S&P 500 over 2+ years)

*   **Analysis:** The MRI suggests a medium investment recommendation. The RSI is neutral. The PPO indicates a slightly bearish signal.  The hybrid signal recommends buying. However, the significant negative expected return is concerning, suggesting caution even with a medium-risk rating. The recent decline in relative divergence confirms the potential for a short-term downtrend.

**4. Recent News & Significant Events**

*   **Key Headlines:**
    *   Ninety One UK Ltd Sells Shares
    *   Billionaire Stanley Druckenmiller's Stock Picks
    *   Natera Announces Publication of Study Findings
    *   Medical Stock Hovers Near Buy Point After Gain
    *   Analysts Bullish on Healthcare Stocks Including Natera
    *   Natera Remains a 'Hold' Despite Growth

*   **Analysis:** Recent news presents a mixed picture. Some positive reports (analyst bullishness, publication of study findings) are counteracted by negative news (share sales). Billionaire's stock picks and "hold" ratings from analysts are neutral.
The news indicates a blend of positive developments (study results, analyst optimism) and potential concerns (share sales, hold ratings), requiring careful assessment.

**4-2. Analyst Opinions**

*   **Consensus:**
    *   Rating: Strong Buy (1.47)
    *   Number of Opinions: 19
    *   Target Price: Avg 246.26 / High 285.00 / Low 186.00

*   **Analysis:** The analyst consensus is strongly bullish with a "Strong Buy" rating and an average target price significantly above the current price. However, the wide range between the high and low target prices suggests some uncertainty among analysts.

**5. Recent Earnings Analysis**

| 날짜        | EPS   | 매출       |
| ----------- | ----- | ---------- |
| 2025-11-07 | -0.64 | 0.59 B$    |
| 2025-08-08 | -0.74 | 0.55 B$    |
| 2025-05-09 | -0.50 | 0.50 B$    |
| 2024-11-12 | -0.26 | 0.44 B$    |
| 2025-11-07 | -0.26 | 0.44 B$    |

*   **Analysis:** The company is not yet profitable as demonstrated by the negative EPS figures. Although Revenue has grown over the periods, EPS performance is inconsistent (not improving steadily).

**6. Financial Information**

*   **Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
| ------------ | ------- | ------------- |
| 2025-09-30 | $0.59B  | 64.91%        |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |

*   **Capital and Profitability:**

| Quarter      | Equity   | ROE      |
| ------------ | -------- | -------- |
| 2025-09-30 | $1.25B  | -6.99%  |
| 2025-06-30 | $1.25B  | -8.10%  |
| 2025-03-31 | $1.24B  | -5.40%  |
| 2024-12-31 | $1.20B  | -4.50%  |
| 2024-09-30 | $0.88B  | -3.60%  |

*   **Analysis:** Revenue is steadily increasing along with the Profit Margin, which is a positive sign. However, the company continues to operate at a loss, as indicated by the negative ROE (Return on Equity). Although equity is steadily rising which is also positive.

**7. Comprehensive Analysis (Summary)**

*   **Overall Assessment:** Natera (NTRA) presents a mixed investment profile.

*   **Positives:**
    *   Historical outperformance of the S&P 500 (high Alpha in certain periods).
    *   Strong revenue growth and improved profit margins.
    *   Strong Buy analyst consensus with a relatively high target price.
    *   Increasing equity.

*   **Negatives:**
    *   High historical volatility (high Beta and MDD).
    *   Negative expected return relative to the S&P 500.
    *   Inconsistent EPS performance and negative ROE, indicating lack of profitability.
    *   Recent share sales.

*   **Recommendations:** The analyst consensus, revenue growth, and improving profit margins are positive signals. However, significant risk is present. Investors should carefully weigh the potential for high returns against the considerable volatility and lack of profitability. Short-term gains might be possible based on market sentiment, but long-term investment requires careful consideration of the underlying financials.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.